HLA-DRB1 and myeloid sarcoma: Of note, heterogeneity was detected between AH 18.2 and the remaining DRB1*03:01 haplotypes: p = 0.05, I2 = 74%, supporting the mentioned stronger effect on MS risk of this AH.